

**JUN Antibody (T239) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP1984c****Specification**

---

**JUN Antibody (T239) Blocking Peptide - Product Information**Primary Accession [P05412](#)**JUN Antibody (T239) Blocking Peptide - Additional Information****Gene ID** 3725**Other Names**

Transcription factor AP-1, Activator protein 1, AP1, Proto-oncogene c-Jun, V-jun avian sarcoma virus 17 oncogene homolog, p39, JUN

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP1984c](/product/products/AP1984c) was selected from the T239 region of human JUN. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**JUN Antibody (T239) Blocking Peptide - Protein Information****Name** JUN**Function**

Transcription factor that recognizes and binds to the AP-1 consensus motif 5'-TGA[GC]TCA-3' (PubMed: [10995748](http://www.uniprot.org/citations/10995748), PubMed: [22083952](http://www.uniprot.org/citations/22083952)). Heterodimerizes with proteins of the FOS family to form an AP-1 transcription complex, thereby enhancing its DNA binding activity to the AP-1 consensus sequence 5'-TGA[GC]TCA-3' and enhancing its transcriptional activity (By similarity). Together with FOSB, plays a role in activation-induced cell death of T cells by binding to the AP-1 promoter site of FASLG/CD95L, and inducing its transcription in response to activation of the TCR/CD3 signaling pathway (PubMed: [12618758](http://www.uniprot.org/citations/12618758)). Promotes activity of NR5A1 when phosphorylated by HIPK3 leading to increased steroidogenic gene expression upon cAMP signaling pathway stimulation (PubMed: [12618758](#)).

href="http://www.uniprot.org/citations/17210646" target="\_blank">17210646</a>). Involved in activated KRAS-mediated transcriptional activation of USP28 in colorectal cancer (CRC) cells (PubMed:<a href="http://www.uniprot.org/citations/24623306" target="\_blank">24623306</a>). Binds to the USP28 promoter in colorectal cancer (CRC) cells (PubMed:<a href="http://www.uniprot.org/citations/24623306" target="\_blank">24623306</a>).

**Cellular Location**

Nucleus.

**Tissue Location**

Expressed in the developing and adult prostate and prostate cancer cells.

**JUN Antibody (T239) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**JUN Antibody (T239) Blocking Peptide - Images****JUN Antibody (T239) Blocking Peptide - Background**

JUN interacts directly with specific target DNA sequences to regulate gene expression.

**JUN Antibody (T239) Blocking Peptide - References**

Fujita,S., J. Mol. Biol. 378 (3), 492-504 (2008)Gan,X.Q., . Cell Biol. 180 (6), 1087-1100 (2008)Yogev,O., Cancer Res. 68 (5), 1398-1406 (2008)